The Muscular Dystrophy Association (MDA) has launched its annual MDA Shamrocks campaign, described as the nation’s largest St. Patrick’s Day-themed fundraiser, to support people living with amyotrophic lateral sclerosis (ALS) and other rare neuromuscular diseases. During the campaign, held throughout February and March, thousands of retailers across the…
MDA launches Shamrocks fundraiser to advance neuromuscular research
An assistant professor from the University of Nevada, Las Vegas, whose work focuses on the molecular mechanisms underlying amyotrophic lateral sclerosis (ALS), has been named the first recipient of the MDA Research Momentum Award, a new honor from the Muscular Dystrophy Association (MDA) for early-career scientists. According to an MDA…
Early treatment with PrimeC, an experimental oral treatment being developed by Neurosense Therapeutics, significantly extended survival in people with amyotrophic lateral sclerosis (ALS) by more than 14 months compared with a six-month delay in treatment initiation. That’s according to additional long-term data from PARADIGM (NCT05357950), a completed…
The amyotrophic lateral sclerosis (ALS) community is mourning the loss of Eric Dane, the “Grey’s Anatomy” star who turned his personal battle with the disease into a crusade for a cure. Dane died Thursday at the age of 53, one year after a diagnosis that saw him trade his…
Sponsored Content
A Look Behind the Care: Inside One Care Partner’s ALS Story
This content is sponsored by Tanabe Pharma America, Inc. (TPA) and is intended for US audiences only. Any other present or future content posted by the contributor, not expressly designated as “Tanabe Pharma America, Inc. – sponsored content” is not associated with TPA. The information provided here is general in…
A U.S. biotech company’s experimental oral therapy, neflamapimod, designed to treat age-related brain disorders, has been selected for inclusion in the EXPERTS-ALS platform study, a U.K. initiative aiming to rapidly test potential treatments for amyotrophic lateral sclerosis (ALS). Developer Cervomed announced in a company press release that its treatment…
A triple combination therapy has shown promise for treating sporadic amyotrophic lateral sclerosis (ALS), according to a new study that used cell models of the disease to screen more than 100 therapeutic compounds. The new cell-based model was created from motor neurons, or nerve cells, derived from people with…
My husband, Todd, finally got in his new wheelchair! After it was delivered in September, I wrote that we needed to have the attendant control reprogrammed. That finally happened, and we’ve been fine-tuning the chair over the past week. Although both are the same brand, there are differences between…
For most people, February is a month filled with hearts and flowers. But for me, it’s all that plus a vibrant display of ALS zebras and a splash of green, pink, blue, and purple. Zebras? You might wonder what a striped animal has to do with a neurological disease…
The ALS Society of Canada (ALS Canada) and Brain Canada have awarded a combined $515,000 to support four early-career clinicians and researchers advancing care and scientific understanding of amyotrophic lateral sclerosis (ALS). ALS Canada and Brain Canada have been partners since 2014, with early support stemming from…
Recent Posts
- How I stimulate my mind while caring for my husband with ALS
- Developer gets OK to expand first-in-human trial of ALS therapy to Europe
- Out-of-pocket ALS costs create heavy financial burden for French families
- RAG-17 shows promise in SOD1-ALS trial, reducing damage markers
- Climbing ALS death rates seen in Finland, not due to aging alone: Study